Kry

1.1 Identity, footprint, and operating model

Kry International AB is headquartered in Stockholm and presents itself as Europe's leading digital-first healthcare provider. The group delivers healthcare every day of the year in Sweden, Norway, the UK, and France, using the Kry brand in Sweden and Norway and the Livi brand in the UK and France. Company legal and privacy materials also make clear that the parent company owns the technical platform while local operating entities and clinicians deliver regulated care in each market. The company's operating model is explicitly digiphysical rather than pure telemedicine. Across its current official surfaces, Kry describes a platform that routes patients between video consultations, self-care guidance, specialist referrals, physical clinics, occupational health, and urgent-care pathways. The annual report describes this as a scalable patient-centred model intended to reduce administrative burden on clinicians and push patients to the right care setting at lower system cost. Public scale disclosures are large but not perfectly harmonised. The global who-we-are page cites 109 million patient coverage, 10 million-plus consultations with a healthcare professional, 900-plus employees, 3,000-plus clinicians and specialists, and 200 million-plus patient reminders sent annually through Mjog. The Swedish about page instead cites 14 million appointments, 4,000-plus healthcare professionals, and 60-plus physical clinics, while the UK about page cites 14 million appointments, 5,000 healthcare professionals, and 54 physical clinics. The 2024 annual report cites almost 11 million consultations, nearly 60 physical clinics, and more than 3,000 healthcare employees across four core markets. These differences are manageable for a narrative overview, but they mean the exact current consultation, clinic, and workforce totals should be treated as range-bound rather than single-source ground truth.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Leadership, board, and governance transition

Kry's founder-led identity remains important, but the company executed a visible leadership transition at the end of 2024. Johannes Schildt moved from CEO to chairman of the board in December 2024, while former deputy CEO and COO Kalle Conneryd Lundgren became CEO and joined the board. Both Kry and Livi described the handover as a shift from founder-led scale-up management toward a structure where Schildt focuses on long-term growth and technology while Lundgren runs operations. The public record supports Lundgren's operational and clinical credibility. Company statements describe him as a surgeon, associate professor of reconstructive plastic surgery, and former COO of Karolinska University Hospital, with academic training spanning theoretical physics, biochemistry, and biophysics. The annual report adds that new board members Yrjö Närhinen and Shrirang Apte joined during the same transition while Martin Mignot stepped down. Governance visibility is still incomplete. The 2024 annual report discloses seven board members at year-end and a male-heavy board composition, but it does not publish a full committee map, investor rights schedule, or board committee charters in public materials. Livi UK's CQC profile confirms that Dr Kalle Conneryd-Lundgren is the nominated individual for the UK regulated service, which gives comfort on direct operating accountability, but investors still need a clearer read on committee oversight, independent director responsibilities, and any special governance attached to recent financing.[CO026, CO027, CO028, CO029, CO030, CO031]

1.3 Financial profile, market traction, and capital picture

The cleanest financial evidence comes from Kry's 2024 annual report and the company's May 2025 results release. Consolidated 2024 net sales were SEK 2,497 million, up 13.3% from 2023, while EBITDA margin improved sharply to -4.4% from -19.5% and EBITA margin improved to -12.3% from -31.5%. Negative group cash flow improved to SEK -125 million from -495 million, and management said February 2025 cash flow was positive. The May 2025 results release also says all markets returned a profit at the end of 2024, which is an important forward-looking signal even though public market-by-market profit detail remains sparse. Operating footprint in Sweden remains the group's anchor. The annual report shows 254,000-plus registered patients at 29 healthcare centres across seven regions and average 2024 employment of 1,591 people group-wide, down from 1,872 in 2023. Country-level revenue in 2024 was SEK 1,788.8 million in Sweden, SEK 417.1 million in France, SEK 247.8 million in the UK, and SEK 35.9 million in Norway. This supports a thesis that Sweden is still the economic core while France and the UK are the most material non-Swedish growth markets. The hardest chapter-one question is capital structure and current valuation. Public official materials document 2024 convertible-loan financing, equity restructuring, and Goldman Sachs-advised ownership simplification, but they do not disclose a clean current post-money valuation. Third-party sources conflict materially: Sacra cites $2.0 billion valuation and €516 million funding tied to the 2022 round, GetLatka reports roughly $232 million ARR, $2.0 billion valuation, $627 million total funding, and 919 employees as of late 2025, Indexed.vc reports $500 million raised in April 2025 and $1.4 billion total raised across nine rounds, and Signalbase publishes a €500 million April 2025 funding claim with sparse source transparency. This evidence is enough to sustain the view that Kry remains a late-stage European healthtech platform with unicorn-level scale, but not enough to resolve the exact latest round size, investor mix, or dilution terms without management data.[CO017, CO018, CO019, CO020, CO021, CO022]

1.4 Milestones, recognition, and early adverse file

Kry's milestone record supports a company that has moved beyond simple video-GP positioning. Over 2024 and 2025 the group adapted to new French regulation, maintained a Good CQC rating for the UK service, pushed deeper into public primary care in Norway, took over Kungsbacka Lättakut in Region Halland, and acquired Hermelinen Group in northern Sweden. Product-side milestones include chronic respiratory digital care pathways through Mjog and a Microsoft-documented Azure OpenAI deployment to automate administrative work and improve patient routing. There is also clear external recognition. Time ranked Kry among the world's most innovative healthtech companies in 2025, and Microsoft featured the company as a customer story showing more than 200 million patient interactions and services delivered in more than 30 spoken languages. These are useful proof points for brand reach and platform ambition, though they are still adjacent to, rather than substitutes for, hard financial disclosure. The adverse file is not empty. Livi UK's 2024 CQC effective report flagged that the service did not always inform patients' own GPs when certain prescriptions would affect ongoing care. More materially, Kry's annual report disclosed two 2025 regional repayment disputes in Sweden: Region Skåne sought SEK 18.8 million and Region Stockholm sought SEK 48 million tied to billing and consultation-structure disagreements, both of which Kry disputes. These items are not thesis-breaking on their own, but they confirm that reimbursement, billing interpretation, and regulated-care execution are live risks rather than abstract footnotes.[CO009, CO023, CO025, CO032, CO033, CO034]

1.5 Exhibits

2.1 Market boundary and evidence-constrained sizing

Kry should not be sized as all of European digital health. The company monetizes a narrower slice: digital-first primary care and adjacent telehealth workflows delivered either through public-system reimbursement, insurer or employer distribution, or direct patient channels that still depend on regulated local care delivery. The annual report, official brand pages, and partner materials show a digiphysical model spanning video consultations, care navigation, physical clinics, occupational-health access, and selected diagnostics. That makes broad digital-health or telehealth TAM pages useful context, but not direct proxies for Kry's capturable market. The best way to handle sizing is with multiple lenses. Analyst pages suggest a very large adjacent market envelope, while company and annual-report disclosures show Kry's realized footprint is much smaller and much more country-specific. Sweden remains the economic core, France has become a scaled teleconsultation market with regulatory normalization, the UK depends heavily on NHS and partner distribution mechanics, and Norway is strategically relevant but financially small. The practical question is therefore not whether digital health is large, but how much reimbursed primary-care access and hybrid care budget in these four countries can migrate to Kry's model. This chapter keeps broad TAM, country-level monetization evidence, and partner-distribution evidence separate on purpose. Published market estimates differ because they use different boundaries, different geographies, and different mixes of software, care delivery, and remote-monitoring spend. Preserving those contradictions is more useful than forcing a fake-precision SAM.[CM001, CM002, CM003, CM004, CM005, CM006]

2.2 Buyer, user, and payer mechanics differ by channel and country

Kry's user is the patient, but its budget owner changes by route to market. In Sweden and parts of France, the public system effectively pays for the clinical act while the provider organization bears the operating model and compliance burden. In the UK, NHS-linked access and regulated service delivery matter, but insurer, employer, and membership channels also appear material through partnerships with Vitality, HA | Wisdom Wellbeing, Klarna, Scan.com, and CloudFit. That gives Kry multiple buyer types, but not one uniform European sales motion. The payer distinction matters strategically. Sacra describes consultation fees as the dominant revenue stream and says public payers account for most consultation-fee revenue, while official and partner materials show that Kry also layers private distribution and referral-style adjacencies onto that base. In other words, Kry is not purely a SaaS vendor and not purely a consumer telemedicine app; it is a care-delivery platform whose monetization depends on a mix of public reimbursement, enterprise distribution, and patient access economics. Competitor and substitute evidence reinforces the same point. HealthHero, Push Doctor, Doctolib, Docplanner, Teladoc, and legacy phone-plus-clinic workflows all attack related access pain from different angles. Some are care-delivery brands, some are workflow or marketplace products, and some are virtual-care infrastructure. Kry therefore competes across a blended market where adoption often depends less on consumer demand than on clinical workflow fit, trust, and channel economics.[CM012, CM013, CM014, CM015, CM016, CM017]

2.3 Growth drivers are strong, but regulatory and workflow friction remain structural

The growth case for Kry is credible. The annual report shows France delivered one million digital appointments in 2024 with roughly 35% growth and about 10% share of remote doctor meetings, while company disclosures show Sweden remains a scaled primary-care base and the UK keeps broad digital-access relevance. IQVIA's 2024 market review likewise argues that digital health is maturing beyond wellness apps toward provider-facing care, diagnostics, decision support, and remote management. Kry's hybrid model fits that direction better than a narrow video-consult thesis. Policy is both tailwind and tax. The European Health Data Space creates a long-run interoperability and digital-health single-market push, and UK digital-access requirements emphasize sustained online consultation capacity and fast response windows. These shifts help normalized digital care, but they also increase implementation burden, integration work, and trust expectations. Public reimbursement systems can accelerate adoption once aligned, yet they also expose operators to billing disputes, rule changes, and procurement friction. The result is a market that can grow without becoming easy. Analyst TAM pages show large spend pools, but company history and competitor outcomes show that operational execution matters more than headline category growth. Market conversion depends on channel mix, physician workflow, regulation, clinic utilization, and proof that hybrid care can scale economically, not just on patient willingness to use digital care.[CM023, CM024, CM025, CM026, CM027, CM028]

2.4 Contradictory estimates and substitute intensity should stay explicit

The cleanest analytical mistake would be to treat every digital-health number as a direct Kry market number. Mordor's Europe digital-health estimate, MarketsandMarkets' telehealth estimate, and Grand View's telehealth framing all describe adjacent opportunity pools, but they do not share the same product boundary, payer mix, or geography as Kry's disclosed operations. They are useful for directional context and for valuation narrative, not for precise underwriting of Kry's near-term SOM. Substitutes also matter more than category pages imply. Kry is displacing traditional GP access, human administrative routing, legacy local clinics, and in some markets digital incumbents that already sit inside insurer or public-system pathways. The Doctorlink discontinuation under HealthHero shows that not every digital-primary-care product survives independently; the category can consolidate or shift from branded apps to embedded infrastructure. That makes buyer-channel durability, not just patient demand, a key diligence question. Investors should therefore keep three unresolved questions open: how much of Kry's future growth comes from public reimbursement versus partner distribution, how much additional clinic and specialist capacity is needed to preserve service quality as digital demand grows, and whether post-2025 market narratives about telehealth scale map to profitable hybrid care rather than gross consultation volume. Those gaps affect both market analysis and valuation later in the report.[CM037, CM038, CM039, CM040, CM041, CM042]

2.5 Exhibits

3.1 The competitive set spans hybrid care, virtual-care brands, marketplaces, and status quo substitutes

Kry does not compete in one clean category. The most direct competitors are other digital-first care providers that combine app-based intake with employed or affiliated clinicians and, in some cases, physical locations. In Sweden that includes Doktor.se and Min Doktor, while Dr.Dropin shows a broader Nordic hybrid model with dense clinic coverage and video access. In the UK, HealthHero, Push Doctor, and ZAVA attack different parts of digital-primary-care and benefits demand. Teladoc represents the largest global virtual-care analogue, though its U.S.-heavy footprint and broader condition-management stack make it more of a strategic reference than a one-for-one local substitute. A second bucket includes patient-access and workflow platforms such as Doctolib and Docplanner. These are not identical to Kry because they do not define themselves purely as care-delivery providers, but they still compete for patient demand, provider relationships, and digital front-door mindshare. They are particularly relevant in France and Europe-wide valuation narratives because they prove that digital healthcare can scale through access, scheduling, and workflow layers rather than only through clinician employment. The third bucket is the status quo. Traditional GP practices, local clinics, telephone triage, and national digital-health infrastructure remain powerful substitutes because they already sit inside trusted reimbursement and care pathways. Kry therefore wins not just by offering a better app, but by proving that its combination of access speed, clinical quality, physical follow-through, and partner distribution is better than both local incumbents and digital rivals.[CP001, CP002, CP003, CP004, CP005, CP006]

3.2 Capability breadth and channel mix matter as much as brand recognition

Kry’s product scope is unusually blended. Official materials and partner pages show video consultations, physical clinics, employer and insurer partnerships, diagnostics adjacency, and multilingual AI-enabled support. Many competitors are strong in only one or two of those dimensions. HealthHero is strong in enterprise and NHS support, Push Doctor emphasizes UK GP access, ZAVA is now highly visible in prescription and weight-loss pathways, while Doctolib and Docplanner are strongest as patient-access and workflow ecosystems. Teladoc brings the broadest global virtual-care platform, including mental health and chronic condition management. This creates an important comparison lens: some rivals compete on breadth, others on channel, and others on geography. Kry’s multi-market operational footprint gives it more regulatory and deployment complexity than single-country rivals, but also creates a stronger learning curve around channel mix and hybrid-care operations. The annual report and official pages suggest Sweden remains the most mature operating base, while France and the UK are more exposed to competitive channel fights. Trust and regulatory posture are also part of the competitive product. Livi UK’s CQC registration and public quality record matter because digital-care competition often hinges on whether patients, partners, and payers believe the service can safely handle ongoing primary-care needs. Competitors with strong consumer brands but weaker local regulatory embedding may be less defensible than they look from brand metrics alone.[CP012, CP013, CP014, CP015, CP016, CP017]

3.3 Switching costs are low for many patients but higher once channels and care pathways are embedded

At the patient level, switching cost in digital care is often modest. A patient can try another app, call a local provider, or use a different partner channel if access or quality disappoints. Multi-homing is therefore likely common on the demand side. But that does not mean all competitive positions are weak. Once an insurer, employer, GP practice, or regional care pathway integrates a provider, the relationship can become harder to dislodge because operations, reimbursement logic, communication, and care follow-up are already wired in. Kry’s partner announcements imply that distribution relationships are meaningful competitive assets. Vitality, HA | Wisdom Wellbeing, Klarna, Scan.com, and CloudFit all increase access to cohorts or adjacencies that a direct-to-consumer app would need to buy expensively through marketing. HealthHero’s UK positioning shows a similar thesis: the most defensible operators are often the ones embedded with employers, NHS flows, or local authorities rather than those relying only on app downloads. The competitive implication is that Kry’s moat is partly operational and channel-based rather than purely technological. That is good news if the company can preserve service quality and renewal economics, but it also means competitors can erode the moat by winning the same partners, improving workflow fit, or narrowing into profitable specialty niches where Kry looks broader but less focused.[CP023, CP024, CP025, CP026, CP027, CP028]

3.4 The moat is real but not impregnable, and adverse competitor evidence cuts both ways

There is clear evidence that the category can scale and also clear evidence that not all models win. Teladoc remains enormous but recently reported year-on-year revenue decline in second-quarter 2026, showing that scale does not remove growth pressure. Doctorlink’s discontinuation as a standalone product under HealthHero suggests consolidation can shift value away from pure consumer-facing brands toward embedded platform or channel models. ZAVA’s weight-loss-heavy messaging suggests focused clinical verticals can also carve out demand that broad primary-care platforms do not automatically own. For Kry, the strongest moat elements appear to be hybrid care delivery, public-system familiarity, partner distribution, and country-level operating knowledge. None is invulnerable. Doctolib and Docplanner show that patient access and provider workflow layers can become powerful fronts of competition without owning the full care journey, while Nordic rivals show that hybrid clinic footprints can be reproduced locally. In other words, Kry has a differentiated position, but not one that eliminates commoditization risk. The durable question is whether Kry can remain the preferred front door in enough channels at once. If patients multi-home, employers rebid, public rules change, or specialist categories unbundle, the company may still grow but lose pricing power or margin quality. Competitive analysis therefore supports a qualified moat thesis: Kry has meaningful differentiation, but durability depends on execution, channel renewal, and local trust, not on a winner-take-most market structure.[CP032, CP033, CP034, CP035, CP036, CP037]

3.5 Exhibits

4.1 Revenue quality, growth, and traction

Kry’s strongest public financial evidence is the 2024 annual report reinforced by the May 2025 results release. Consolidated net sales reached SEK 2,497 million in 2024, up 13.3% year over year, while management described 2024 as its best results to date and said revenue had increased 22% since 2022. That top-line scale matters because it separates Kry from smaller telehealth narratives and gives it a real base from which to evaluate margin improvement, channel mix, and capital needs. Public sources also suggest the revenue base is not purely one-dimensional. Sacra describes three primary revenue streams: consultation fees, SaaS sales to doctors and clinics, and referral payments from partners such as pharmacies and labs. The company’s partner announcements and Mjog footprint make that mix plausible, but the annual report does not publish a clean quantitative revenue split by stream. Investors can therefore believe the business has more than one monetization lever while still treating exact mix disclosure as incomplete. Traction metrics support revenue credibility. Sweden remains the anchor with 250,000-plus listed patients and a significant primary-care base; France delivered one million digital appointments in 2024; and post-acquisition materials around Hermelinen indicate that Kry continues to add physical-service capacity as part of the commercial model. The resulting picture is of a scaled hybrid healthcare operator with meaningful revenue, not a pure consumer app chasing utilization without a visible business model.[CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Margin path improved sharply, but cost structure still reflects a healthcare operator

Kry’s reported margin direction improved dramatically in 2024. EBITDA margin improved to -4.4% from -19.5%, EBITA margin improved to -12.3% from -31.5%, and negative cash flow improved to SEK -125 million from SEK -495 million. The results release then added two important forward signals: all markets returned a profit at the end of 2024, and February 2025 cash flow was positive. Those are meaningful statements for a business often viewed through a telehealth skepticism lens. At the same time, nothing in the public record suggests Kry has escaped the basic cost realities of care delivery. The model still depends on clinicians, care operations, compliance, customer support, and a growing physical footprint. Workforce and clinic disclosures support a discipline story more than a pure software-margin story: average group employment fell to 1,591 in 2024 from 1,872 in 2023, which likely helped the cost base, but the business remains structurally more labor- and operations-intensive than a workflow-only SaaS company. The best interpretation is that Kry has substantially improved efficiency without yet becoming easy to underwrite as a software-like margin business. Public evidence supports an improving margin path, but it does not reveal gross margin, contribution margin by market, clinician utilization by channel, or the extent to which recent gains came from cost actions versus durable revenue quality.[CI011, CI012, CI013, CI014, CI015, CI016]

4.3 Geographic concentration and hybrid go-to-market shape the financial model

Kry’s disclosed revenue mix confirms that Sweden is still the economic core. The annual report shows 2024 revenue of SEK 1,788.8 million in Sweden, SEK 417.1 million in France, SEK 247.8 million in the UK, and SEK 35.9 million in Norway. That matters because it makes the company less of a balanced four-country portfolio than a Swedish anchor with two meaningful expansion markets and one small outpost. Investors should read the France and UK stories as important growth vectors, but not yet as co-equal earnings engines. The go-to-market model is also financially unusual. Kry is not only selling software or only buying app traffic. It combines public-system care delivery, digital front-door access, insurer and employer distribution, and a clinic network that can absorb in-person demand when needed. The Hermelinen acquisition underscores this hybrid logic by adding northern-Sweden capacity and specialty services rather than just more digital demand. Financially, that can improve defensibility and care resolution, but it also raises integration, utilization, and operating-leverage questions. This is why capital intensity cannot be reduced to cloud spend or engineering headcount. Kry appears to be improving because its hybrid model is maturing, not because it has transformed into a lightweight software marketplace. That is investable if the company can keep utilization and channel economics disciplined, but it makes clinic-level and market-level contribution margins critical diligence asks.[CI021, CI022, CI023, CI024, CI025, CI026]

4.4 Capital adequacy looks better, but financing transparency is still uneven

The encouraging part of Kry’s capital story is visible: margin and cash-flow improvements are real, management says the group reached positive cash flow in February 2025, and the business is large enough that investors are not evaluating a pre-revenue startup. The less encouraging part is that public evidence still does not fully resolve the current balance sheet or latest valuation. The annual report discloses financing and ownership-structure work in 2024, while third-party trackers disagree on total funding, current implied value, and the meaning of recent secondary-market indications. Tracxn, WOWLS, Forge, Accumeo, Indexed.vc, GetLatka, and Signalbase all help frame the financing narrative, but they do not align cleanly. Tracxn shows $703 million raised over seven rounds with a $2 billion valuation attached to the 2021 Series D; Indexed.vc and Signalbase add later-round or later-funding narratives; Forge and Accumeo indicate an active private-market or secondary-market context; WOWLS argues the 2021 valuation may overstate current fundamentals. That set is useful for scenario framing, but not strong enough to substitute for direct company disclosure. The financial bottom line is therefore nuanced. Kry no longer looks obviously financing-constrained on public evidence alone, but it also does not provide enough direct disclosure to eliminate financing dependency as a risk. Investors can underwrite improving performance, yet should still ask for cash balance, debt terms, covenant detail, preference stack, and planned use of funds before assuming the company can self-fund all next-stage growth.[CI031, CI032, CI033, CI034, CI035, CI036]

4.5 Financial verdict

Kry’s financial case has crossed the threshold from narrative-heavy to evidence-bearing. The company has meaningful scale, credible year-on-year revenue growth, sharply improved margins, and concrete signs that management has become more disciplined about cash. Those are not trivial achievements in a telehealth sector where public and private markets have become much more skeptical. The remaining problem is not top-line credibility but underwriting completeness. Public data still does not explain how much profit durability comes from Sweden versus expansion markets, how profitable partner channels are after service costs, how much physical capacity raises returns versus complexity, or what the current financing stack really looks like after 2024-2025 changes. The company is therefore financially stronger than a generic telehealth bear case implies, but still not fully transparent enough for price-insensitive capital. Netting the evidence together, the financial verdict is favorable on revenue quality and trajectory, positive but cautious on margin path, and incomplete on capital adequacy. A disciplined investor should treat 2024-2025 as proof of operational progress while making balance-sheet detail, market-level unit economics, and channel profitability the non-negotiable asks before underwriting any new round or secondary purchase.[CI042, CI043, CI044, CI045, CI046]

4.6 Exhibits

5.1 The product is a hybrid care workflow, not just a telemedicine app

Kry’s core product is a patient-care journey that begins digitally and can end digitally or physically depending on need. Official Kry and Livi pages describe booking, symptom intake, video consultations, prescriptions, follow-up, and referral into physical clinics or downstream care. The patient promise is speed and convenience, but the deeper product logic is routing: get the patient to the right clinician, at the right level of care, with less administrative friction than a traditional phone-first primary-care workflow. That workflow is more visible on current product surfaces than a traditional feature list. Kry’s English site highlights app-based access to doctors, nurses, psychologists, and physiotherapists, 24/7 availability, and continuity of care through follow-up and clinic visits. Livi France explicitly frames reimbursement, e-prescriptions, specialist referrals, and orientation toward in-person care when needed. Norway materials show the company also packages digital solutions for fastlege practices, including digital reception, video visits, and cloud-based operational support. This means the product definition should not be reduced to ‘video GP.’ Kry is building a digital front door plus an operating layer for hybrid primary care, with variations by country and channel. The public evidence is rich enough to define the workflow clearly even if it is not rich enough to reconstruct deep system architecture.[CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Modules and assets span patient app, clinician tooling, partner solutions, and clinic operations

Kry’s product stack appears to have at least four distinct layers. First is the consumer or patient layer: booking, video consultations, digital care follow-up, pricing and payment logic, and localized experiences by market. Second is the clinician and operations layer that supports consultations, prescriptions, scheduling, routing, and continuation of care. Third is the partner and enterprise layer used by NHS-linked, insurer, employer, and other institutional customers. Fourth is the Mjog communication platform, which extends beyond the Kry app into practice workflow, messaging, reminders, video, and remote monitoring. Mjog is particularly important because it shows Kry owns not only a care-delivery brand but also a workflow asset with standalone value. Public Mjog materials describe integration with clinical systems, appointment reminders, batch messaging, clinician toolbar workflows, remote monitoring questionnaires, and practice websites built to NHS guidelines and accessibility rules. Norway’s fastlege-support page points in a similar direction by describing digital reception, cloud journals, staffing support, and process tooling for local practices. The overall asset map therefore looks less like a single product and more like a modular operating stack. That can increase defensibility because it widens integration points and use cases, but it also makes deployment, support, and product coherence harder to manage across markets.[CE010, CE011, CE012, CE013, CE014, CE015]

5.3 Integration and deployment are central to the product promise

The public technology story emphasizes usable deployment rather than frontier R&D. Kry’s patient products show identity-linked booking, app-based follow-up, and country-specific reimbursement or clinic routing. Mjog’s public pages emphasize integration with the clinical system, reminders built around actual slot types, video and SMS inside the clinician workflow, and structured patient questionnaires for remote monitoring. Norway’s fastlege materials similarly focus on digital reception, cloud journal systems, operations support, and day-to-day efficiency. This matters because digital healthcare fails less often from missing features than from deployment friction and workflow disruption. Kry’s product positioning consistently aims at reducing phone load, improving access, and making clinicians easier to reach without forcing them out of their normal operating environment. The support and knowledge-base materials also suggest the company treats training, service status, and technical support as core parts of the product, not just afterthoughts. Reliability evidence is still more operational than technical. CQC quality status, Mjog support materials, and patient-facing FAQs provide comfort that the platform is live and actively used, but public sources do not disclose uptime, incident frequency, infrastructure topology, or security testing cadence. Reliability is therefore directionally credible but not deeply transparent.[CE020, CE021, CE022, CE023, CE024, CE025]

5.4 Differentiation comes from operating model, local integration, and trust controls

Kry’s differentiation is stronger in system design and local execution than in publicly documented core algorithms. The company claims more than 200 million patient interactions, broad language coverage, 24/7 clinician access, and a hybrid digital-physical network. Microsoft’s case study adds Azure OpenAI-enabled workflow automation, while Mjog materials add workflow automation and communication tools for external practices. Those signals collectively support a view that Kry has meaningful product depth, even if the public technical surface is not developer-heavy. Trust and compliance controls are also central to the product. Legal materials explicitly separate the platform company from local care providers, privacy and UK legal pages define responsibilities and notices, Livi’s download page links to safeguarding and vulnerability-disclosure materials, and the CQC record provides an external regulatory quality anchor. These are not decorative. In healthcare, privacy posture, safeguarding, and clinical-accountability structures are product features because they determine whether patients, regulators, and channel partners will trust the workflow. The limitation is that public evidence does not show deep architecture diagrams, patents, performance benchmarks, or a large developer ecosystem. That makes Kry look more like an operationally sophisticated healthcare platform than a pure technology moat story. For investors, that is acceptable if adoption and outcomes stay strong, but it means diligence should focus on real workflow advantage, support costs, and safety controls rather than on assumed software magic.[CE028, CE029, CE030, CE031, CE032, CE033]

5.5 Exhibits

6.1 Kry serves patients directly, but the real customer map includes payers, employers, insurers, and public systems

Kry’s customer picture is multi-sided. The patient is the end user and often the visible beneficiary, but channel evidence shows that public systems, employers, insurers, and institutional partners also shape access and value capture. In Sweden, listed patients and clinic membership indicate an ongoing primary-care relationship rather than one-off teleconsult usage. In France, reimbursable teleconsultation means the patient experience sits inside the public system. In the UK, Livi’s partner pages explicitly target ICSs, ICBs, urgent care services, PCNs, insurers, and employers. This matters because revenue durability depends on more than patient downloads. Some usage comes from patients returning voluntarily for care, but some comes from contracts, pathways, and partner relationships that embed Kry into access infrastructure. That is a stronger distribution story than a pure D2C healthcare app, yet it also creates concentration and procurement risk if one or two channels dominate growth. The best public segmentation lens is therefore buyer/user/payer/channel. Patients, families, NHS-linked users, listed primary-care patients, insurer members, employer populations, and partner-referred users all appear in the retained evidence. The chapter evaluates adoption and durability through that lens rather than pretending all traffic is the same kind of customer relationship.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Adoption signals are strong, with better named proof on channels than on net revenue retention

Kry’s public adoption signals are substantial. Official pages cite 14 million appointments or consultations on some surfaces, 10 million-plus patients treated on app-store surfaces, 250,000-plus listed patients in Sweden, 1 million digital appointments in France in 2024, and 200 million-plus patient interactions in the Microsoft case study. Customer-facing app-store reviews add very large review counts and high average scores. Taken together, that is enough to believe the service has broad real-world usage and repeat demand. Named customer proof is strongest in the UK partner channel. Vitality, HA | Wisdom Wellbeing, Klarna, Scan.com, and CloudFit show that employers, insurers, and adjacent health partners trust Kry or Livi enough to distribute services to their users. Livi’s UK partner homepage also positions the company for ICSs, ICBs, urgent care services, GP practices, and insurers, suggesting that institutional adoption is a core part of the expansion playbook. The weaker area is classic software-style retention disclosure. Public sources do not provide NRR, GRR, churn, cohort retention, or contract-renewal metrics. Customer proof is therefore strong on breadth and reference quality, but incomplete on economic durability.[CU010, CU011, CU012, CU013, CU014, CU015]

6.3 Durability likely comes from continuity and channels, but concentration risk remains

There are real reasons to believe customer relationships can be durable. Sweden’s listed-patient model creates an ongoing relationship; partner channels can renew over multi-year periods; and hybrid care lets Kry follow the patient from digital intake into ongoing or physical care. These features should improve repeat use and make the platform more valuable than a single consultation. The app-store descriptions also emphasize renewals, referrals, specialist access, and chronic or family use cases that support recurring engagement. But concentration risk should remain explicit. Sweden is still the economic core; large public or partner channels in the UK may be disproportionately important to marginal growth; and France’s teleconsult usage could still depend heavily on reimbursement and access conditions outside Kry’s control. Public evidence shows expansion potential, but not whether it is balanced across a diversified customer portfolio. The practical implication is that customer quality looks favorable, but customer economics are not yet fully de-risked. Investors should assume there is meaningful repeat usage and partner durability, while still demanding cohort, renewal, and concentration data before treating the customer base as fully sticky or diversified.[CU020, CU021, CU022, CU023, CU024, CU025]

6.4 High satisfaction is real, but service-access complaints and opaque renewal metrics still matter

Customer evidence is broadly positive, but not uniformly so. Apple and Google app-store pages show very high ratings and large review counts, which are meaningful at Kry’s scale. AppBrain and app-store excerpts also preserve occasional complaints about appointment availability, technical issues, or being routed to physical care after a paid or time-consuming digital step. Those comments do not overpower the overall positive signal, but they do show where customer experience can erode if operational capacity tightens. The main diligence gap is therefore not whether customers exist or like the product in general. It is whether the strongest visible channels—listed patients, partner contracts, insurer distribution, and high-frequency app users—translate into durable, economically attractive cohorts. Without contract terms, retention curves, NRR/GRR, or top-channel concentration, a customer chapter can validate demand but not fully underwrite value capture. The customer verdict is favorable on breadth, adoption, and reference quality; positive but cautious on durability; and incomplete on concentration and renewal economics. For later valuation work, that means customers support the thesis, but they do not yet remove the need for disciplined channel-level diligence.[CU028, CU029, CU030, CU031, CU032, CU033]

6.5 Exhibits

7.1 Kry’s most material risks sit in reimbursement, regulated execution, and transparency rather than pure product demand

The public record suggests that Kry’s biggest risks are those of a scaled healthcare operator, not those of a pre-product startup. Demand risk exists, but it is not the headline issue: millions of consultations, high app ratings, and visible partner demand show that customers want the service. The sharper questions are whether public reimbursement remains supportive, whether cross-country regulated-care execution stays clean, whether partner and channel dependence becomes concentrated, and whether the balance sheet is strong enough to absorb shocks. Two risks stand out immediately from primary sources. First, the annual report discloses Swedish regional repayment disputes tied to billing and consultation-structure disagreements. Second, the UK CQC effective report flagged a care-coordination weakness around informing patients’ own GPs when certain prescriptions were issued. Neither item alone breaks the thesis, but together they show that revenue-recognition and clinical-governance risks are real, not hypothetical. The rest of the risk picture follows logically: sensitive-data compliance, hybrid operational complexity, clinician-capacity pressure, partner concentration, and financing opacity. The company has visible mitigations on several fronts, but residual exposure remains material enough that investors should treat risk diligence as core, not peripheral.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Regulatory, legal, and quality risk are structural to the model

Kry operates across heavily regulated healthcare systems, so legal and quality risk sit at the center of the investment case. The UK CQC record is directionally positive because Livi UK is rated Good overall and well-led, but the effective report still identified a material care-process weakness: some prescriptions were not always communicated to patients’ own GPs. Public evidence therefore supports both trust and residual quality risk at the same time. In Sweden, the annual report discloses region-level claims for repayment tied to billing and consultation structure. Kry disputes those claims, but the key analytical point is broader: the model depends on how regional or national actors interpret remote-care billing, scope, and process rules. If interpretations tighten or disputes multiply, revenue quality and margin progress can reverse quickly. Privacy, safeguarding, and legal-entity structure add another layer. Kry and Livi publish privacy, EULA, cookies, and local notice materials, while download-page links reference safeguarding and vulnerability-disclosure content. That is comforting from a control-design perspective, yet the volume of legal surfaces also reflects how compliance-heavy the business is. In healthcare, that burden is a permanent operating reality, not a one-time setup cost.[CR010, CR011, CR012, CR013, CR014, CR015]

7.3 Operational and dependency risks flow from hybrid care, channel embedding, and platform dependence

Kry’s hybrid model improves care resolution, but it introduces operational risk that pure software businesses do not bear. Clinics, urgent care, diagnostics handoffs, local clinician staffing, and cross-border process variants all create more points of failure. App-directory complaints about appointment availability or being routed to physical care after a digital step are small relative to overall positive satisfaction, but they show how easily experience can degrade if capacity or triage quality slips. Partner dependence is the second major operational risk. In the UK especially, Kry’s growth narrative is intertwined with partner distribution and public-system relationships. Vitality, HA | Wisdom Wellbeing, Klarna, CloudFit, Scan.com, ICSs, ICBs, and GP-practice channels expand reach, but they also create renewal, pricing, and concentration risk. If embedded channels weaken or are rebid, the company may retain demand but lose profitable distribution. Technology and cloud dependence also matter even if public infrastructure detail is sparse. Microsoft’s case study and Mjog’s communication stack suggest real reliance on cloud-based workflow, AI tooling, and integrated digital channels. That is normal for a modern health platform, but it means outages, security incidents, or major vendor dependence could affect both care delivery and partner trust at once.[CR020, CR021, CR022, CR023, CR024, CR025]

7.4 Financial and model risk are improving, but not fully resolved

The financial model has improved materially, but investors should resist turning improvement into immunity. Margin and cash-flow progress reduce risk, yet the business still operates in a sector with heavy skepticism about telehealth economics. Public trackers disagree on the current valuation context, and the company does not publish enough balance-sheet detail to eliminate financing dependency or preference-overhang risk. A broader model risk also remains: telehealth can produce high usage without necessarily producing software-like margins. Kry’s hybrid model is arguably better positioned than pure-video peers because it can route into physical care and partner workflows, but it also carries capital intensity and staffing complexity. That means the model can fail either through reimbursement deterioration or through an inability to maintain operational efficiency at scale. Mitigations are visible. Kry has improved profitability, formal legal and privacy frameworks exist, the UK service is regulated and externally reviewed, support and training functions are public, and the company has diversified channels beyond one pure app. The residual risk is therefore not that management has ignored controls, but that healthcare delivery is a hard business where even well-controlled operators can face sudden policy, quality, or funding shocks.[CR029, CR030, CR031, CR032, CR033, CR034]

7.5 Exhibits

8.1 The company thesis is stronger than the current valuation evidence

The bullish case for Kry is straightforward and supported by earlier chapters. The company has real scale, improving financials, a hybrid care model, meaningful customer adoption, and a product that looks more operationally serious than many telehealth narratives imply. Europe’s healthcare access problems are persistent, and Kry has already shown that it can win demand across Sweden, France, the UK, and Norway. The anti-thesis is equally important. Public evidence on current valuation is conflicted, recent financing terms are not cleanly disclosed, and the sector has already demonstrated how quickly telehealth multiples can collapse when reimbursement or margins disappoint. Kry’s own progress does not erase the lessons from Babylon’s collapse, Teladoc’s post-peak re-rating, or broader skepticism about labor-intensive care models being valued like software. That makes valuation here highly price-sensitive. If an investor can enter meaningfully below the old 2021-style peak framing, with access to primary diligence on balance sheet, cohort economics, and partner concentration, the opportunity is interesting. If the ask still assumes a premium, software-like multiple without new disclosure, the prudent stance is to track or research more rather than stretch.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Public valuation context is noisy, so comparisons matter more than one tracker number

The cleanest valuation anchor in the retained evidence is the April 2021 Series D valuation of $2 billion, repeated by Tracxn and reflected indirectly in other trackers. Beyond that, the picture fragments. Indexed.vc and Signalbase point toward later financing narratives; Tracxn shows $703 million raised over seven rounds; Forge and Accumeo indicate private-market or secondary-market context but limited transparency; WOWLS argues the 2021 mark likely overstates current reality; and secondary-estimate sites disagree on revenue, employees, and total funding. None of those should be mistaken for authoritative current fair value on their own. Comparable framing is therefore more useful than pretending the latest tracker is truth. Public telehealth and digital-health comparables such as Teladoc, Hims & Hers, Doximity, and workflow-led platforms show a wide spread between labor-heavy virtual care, higher-margin digital health, and clinician productivity tools. Kry sits somewhere between those categories: more operationally complex than software networks, but stronger and more integrated than a pure virtual-consult brand. For that reason, the valuation conclusion should be expressed as a range and a discipline, not as a single spurious point estimate. The more Kry proves durable partner economics, clinic contribution margins, and stable reimbursement, the closer it can justify premium healthtech multiples. Without that proof, the older unicorn mark is a ceiling reference, not an automatic fair-value floor.[CV010, CV011, CV012, CV013, CV014, CV015]

8.3 Bull/base/bear outcomes should reflect both company quality and evidence quality

A reasonable scenario framework starts from what is known: 2024 revenue near SEK 2.5 billion, better margins, and a business that appears operationally stronger than generic telehealth skeptics assume. It then discounts for what is not known: current cap table terms, cash balance, contract durability, partner concentration, and the exact price or dilution of any 2025 financing. This naturally leads to a broader range than a mature public comp would need. In the bear case, telehealth multiple compression, reimbursement friction, and hidden financing overhangs could pull defensible value materially below the 2021 peak mark. In the base case, improved financial performance and hybrid care quality support a substantial business value, but still not enough to blindly affirm a full peak-era software-style premium. In the bull case, Kry proves sustainable profitability improvements, channel durability, and a credible integrated-care platform advantage, allowing value to hold near or modestly above the old unicorn anchor. Return logic therefore depends heavily on entry price and evidence unlocks. If the buyer is paying near a stale headline valuation without receiving new balance-sheet and cohort data, upside is too evidence-light. If the buyer can enter at a discount to legacy marks and secure diligence rights, the asymmetry improves materially.[CV020, CV021, CV022, CV023, CV024, CV025]

8.4 Recommendation: track / research more unless price and disclosure improve

The recommendation here is not a no-quality verdict; it is a no-false-precision verdict. Kry clearly merits serious attention because it has built a scaled European digital-health platform with improving economics, strong customer proof, and a differentiated hybrid model. But the public record still leaves too much uncertainty around current valuation, financing terms, concentration, and true channel economics to justify a confident buy call at an unverified premium price. Accordingly, the most defensible stance is research more or track, with a bias to engage if access is possible and pricing is disciplined. A move toward buy would require cleaner evidence on cash and debt, recent primary or secondary pricing, partner-renewal durability, and market-level profitability. A move toward pass would become more likely if the seller insists on a peak-era mark despite limited disclosure or if new reimbursement or quality issues appear. In short: the company case is credible, the evidence case is partial, and the price case is unresolved. That combination is exactly where disciplined investors should stay selective.[CV029, CV030, CV031, CV032, CV033, CV034]

8.5 Exhibits